UNC Health Medication Formulary
Add Formweb to your mobile device
System Formulary Update
Upadacitinib (Rinvoq) 45 mg ER tablet
September 16, 2025
Situation: Upadacitinib (Rinvoq) 45 mg ER tablet was approved for addition to the UNC Health System Formulary at the System Pharmacy and Therapeutics Committee Meeting.
Background: The following medication was reviewed: Upadacitinib (Rinvoq) 45 mg ER tablet
Assessment/Recommendation: System P&T voted to include the following product to the UNC Health formulary with restriction: Upadacitinib (Rinvoq) 45 mg ER tablet
RESTRICTED to the following:
-
Approval by gastroenterology or pediatric gastroenterology attending
-
Previous treatment failure with or contraindication to anti-TNF agent